Repository of Research and Investigative Information

Repository of Research and Investigative Information

Baqiyatallah University of Medical Sciences

Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19

(2020) Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19. Journal of Clinical Pharmacy and Therapeutics. pp. 1515-1519. ISSN 0269-4727

[img] Text
Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injuryacute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.pdf

Download (126kB)

Official URL: http://apps.webofknowledge.com/InboundService.do?F...

Abstract

What is known and objective: This article summarizes the effects of sivelestat on acute lung injury/acute respiratory distress syndrome (ALI/ARDS) or ARDS with coagulopathy, both of which are frequently seen in patients with COVID-19. Comment: COVID-19 patients are more susceptible to thromboembolic events, including disseminated intravascular coagulation (DIC). Various studies have emphasized the role of neutrophil elastase (NE) in the development of DIC in patients with ARDS and sepsis. It has been shown that NE inhibition by sivelestat mitigates ALI through amelioration of injuries in alveolar epithelium and vascular endothelium, as well as reversing the neutrophil-mediated increased vascular permeability. What is new and conclusions: Sivelestat, a selective NE inhibitor, has not been evaluated for its possible therapeutic effects against SARS-CoV-2 infection. Based on its promising beneficial effects in underlying complications of COVID-19, sivelestat could be considered as a promising modality for better management of COVID-19-induced ALI/ARDS or coagulopathy.

Item Type: Article
Keywords: acute lung injury/acute respiratory distress syndrome coagulopathy COVID-19 neutrophil elastase inhibito sivelestat nf-kappa-b inflammatory mediators cytokine storm tnf-alpha pathogenesis ono-5046 activation stress ards Pharmacology & Pharmacy
Page Range: pp. 1515-1519
Journal or Publication Title: Journal of Clinical Pharmacy and Therapeutics
Journal Index: ISI
Volume: 45
Number: 6
Identification Number: https://doi.org/10.1111/jcpt.13251
ISSN: 0269-4727
Depositing User: مهندس مهدی شریفی
URI: http://eprints.bmsu.ac.ir/id/eprint/8651

Actions (login required)

View Item View Item